Liege, Belgium, 13 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the issuance of a put option notice, according to the terms of the capital commitment agreement signed with LDA Capital Limited on April 24, 2020. Under the terms of this agreement extended in April 2022, LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years (until April 2025) in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement. The first three drawings resulted in the issuance of 916,153 shares for a total amount of approximately EUR 17 million, leaving EUR 58 million available to Mithra.

Liege, Belgium, 12 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that several presentations focusing on therapeutic opportunities for estetrol (E4) will be held at the 20th World Congress of the International Society of Gynecological Endocrinology (ISGE) taking place from 11-14 May 2022 in Florence, Italy. A selection of these presentations will be made available in the coming days in the investors section of the company’s website.

Liege, Belgium, 06 May 2022 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Glenernie Capital Ltd, with registered offices at Smithson Plaza, 13th Floor, 25 St. James’s Street, London SW1A 1HA, on 3, May 2022. Glenernie Capital has notified Mithra that it has exceeded the statutory 3% threshold on 28, April 2022.